{"gene":"BAP1","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":2010,"finding":"BAP1 contains a ubiquitin carboxyl-terminal hydrolase (UCH) domain, and inactivating mutations including those affecting this UCH domain are found in metastasizing uveal melanomas, implicating BAP1 deubiquitinase activity in tumor suppression.","method":"Exome capture and massively parallel sequencing; mutation mapping to functional domain","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — foundational study, replicated across many subsequent labs, mutations directly map to UCH catalytic domain","pmids":["21051595"],"is_preprint":false},{"year":2009,"finding":"BAP1 interacts with and deubiquitinates host cell factor-1 (HCF-1) via a dedicated HCF-1 binding motif (HBM), and this interaction is required for BAP1-mediated cell proliferation regulation; HCF-1N is modified with Lys-48-linked polyubiquitin on its Kelch domain, which BAP1 removes.","method":"Mass spectrometry of co-purified proteins, Co-IP, in vitro deubiquitination assay, RNAi, dominant-negative overexpression","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal Co-IP, biochemical DUB assay, functional rescue with HBM mutant, replicated by subsequent studies","pmids":["19815555"],"is_preprint":false},{"year":2012,"finding":"BAP1 co-fractionates with and binds HCF-1 in renal cell carcinoma tumorgrafts; mutations disrupting the HCF-1 binding motif impair BAP1-mediated suppression of cell proliferation but not deubiquitination of H2AK119ub1, indicating separable functions.","method":"Tumorgraft fractionation, Co-IP, cell proliferation assays, H2AK119ub1 deubiquitination assay, domain mutation analysis","journal":"Nature Genetics","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods in primary tumor material, functional separation of HCF-1 binding from H2A DUB activity","pmids":["22683710"],"is_preprint":false},{"year":2013,"finding":"BAP1 is required for efficient assembly of homologous recombination factors BRCA1 and RAD51 at ionizing radiation-induced foci; BAP1 is recruited to DSB sites, and both its catalytic activity and IR-induced phosphorylation at six sites are critical for DSB repair by HR.","method":"RNAi screen, DT40 knockout cells, immunofluorescence foci assay, ChIP at I-SceI DSB site, phosphorylation site mutagenesis","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — clean KO with multiple phenotypic readouts, active-site and phospho-site mutagenesis, direct chromatin recruitment assay","pmids":["24347639"],"is_preprint":false},{"year":2014,"finding":"BAP1 deubiquitinates and stabilizes INO80 (catalytic ATPase of the INO80 chromatin-remodelling complex) and recruits it to replication forks via ubiquitinated H2A, promoting replication fork progression during normal DNA synthesis.","method":"Co-IP, in vitro deubiquitination assay, ChIP at replication forks, BAP1-defective cancer cell lines, mouse embryo Ino80 knockout","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical DUB assay, direct ChIP at forks, genetic validation in BAP1-defective cancer cells and mouse embryos","pmids":["25283999"],"is_preprint":false},{"year":2014,"finding":"BAP1 acts as a deubiquitinase for histone H2A and is recruited to FoxK2 target gene promoters through an interaction with the forkhead-associated domain of FoxK2 (which binds phospho-Thr493 on BAP1); BAP1 bridges FoxK2 and HCF-1 in a ternary complex and represses FoxK2 target genes in opposition to the Ring1B-Bmi1 E3 ligase.","method":"ChIP, Co-IP, reporter assays, phospho-specific interaction mapping, RNAi knockdown","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, specific phospho-residue mapped, functional epistasis with Ring1B-Bmi1","pmids":["25451922"],"is_preprint":false},{"year":2015,"finding":"BAP1 forms two mutually exclusive complexes with ASXL1 and ASXL2 via their ASXM domains interacting with BAP1's C-terminal domain (CTD); these interactions generate a composite ubiquitin-binding interface (CUBI) required for H2AK119 deubiquitination, and ASXL2 interaction also regulates cell senescence.","method":"Co-IP, in vitro deubiquitination assay, cancer-associated mutation analysis, cell proliferation and senescence assays","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical reconstitution of DUB activity, structural domain mapping, cancer mutation validation with multiple orthogonal methods","pmids":["26416890"],"is_preprint":false},{"year":2015,"finding":"BAP1 acts as a bona fide deubiquitinase for KLF5 transcription factor in breast cancer cells, directly interacting with KLF5 and stabilizing it by removing ubiquitin; KLF5 is a component of the BAP1/HCF-1 complex, which promotes cell cycle progression partly by inhibiting p27 expression.","method":"Genome-wide siRNA DUB screen, Co-IP, in vitro deubiquitination assay, rescue experiments with KLF5 re-expression, xenograft models","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1-2 — systematic screen confirmed by biochemical DUB assay, functional rescue in vivo","pmids":["26419610"],"is_preprint":false},{"year":2015,"finding":"Loss of BAP1 results in decreased H4K20 monomethylation (H4K20me1) and increased H3K27me3 via upregulation of EZH2; conditional co-deletion of Bap1 and Ezh2 in mice abrogates myeloid progenitor expansion caused by Bap1 loss alone, placing BAP1 upstream of the EZH2/PRC2 pathway.","method":"Mouse conditional knockout (Bap1/Ezh2 double KO), ChIP-seq (H3K27me3, H4K20me1), pharmacological EZH2 inhibition","journal":"Nature Medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo (double KO), ChIP-seq, pharmacological validation, replicated with SETD8 re-expression","pmids":["26437366"],"is_preprint":false},{"year":2016,"finding":"BAP1's C-terminal extension auto-recruits BAP1 to nucleosomes independently of the acidic patch; the DEUBAD domains of ASXL1, ASXL2, or ASXL3 then activate BAP1 by increasing its affinity for ubiquitin on H2A to drive deubiquitination specifically of H2AK119Ub (Polycomb modification) but not H2AK13/15Ub (DNA damage modification).","method":"In vitro reconstituted deubiquitination assay with purified proteins, nucleosome-binding assays, domain deletion/mutation analysis","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with purified components, mechanistic dissection of substrate specificity and activation mechanism","pmids":["26739236"],"is_preprint":false},{"year":2017,"finding":"BAP1 localizes to the endoplasmic reticulum (ER), where it binds, deubiquitylates, and stabilizes the type 3 inositol-1,4,5-trisphosphate receptor (IP3R3), thereby modulating Ca2+ release from the ER into the cytosol and mitochondria and promoting apoptosis; reduced BAP1 in BAP1+/- carriers decreases IP3R3 levels and Ca2+ flux, preventing apoptosis after genotoxic stress.","method":"Subcellular fractionation, ER localization imaging, Co-IP, in vitro deubiquitination assay, Ca2+ flux measurements, BAP1+/- patient cell lines, cellular transformation assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (localization, DUB assay, Ca2+ flux, functional transformation), validated in patient-derived cells","pmids":["28614305"],"is_preprint":false},{"year":2017,"finding":"BAP1 decreases H2Aub occupancy at the SLC7A11 (cystine transporter) promoter and represses SLC7A11 expression in a deubiquitinating-dependent manner, inhibiting cystine uptake and leading to elevated lipid peroxidation and ferroptosis; cancer-associated BAP1 mutants lose ability to repress SLC7A11 and promote ferroptosis.","method":"ChIP-seq (H2Aub), RNA-seq, CRISPR/siRNA knockdown, ferroptosis assays, lipid peroxidation measurement, xenograft tumor models","journal":"Nature Cell Biology","confidence":"High","confidence_rationale":"Tier 1-2 — integrated epigenomic + transcriptomic + functional data, catalytic mutant validation, in vivo tumor models","pmids":["30202049"],"is_preprint":false},{"year":2017,"finding":"BAP1 inhibits glucose deprivation-induced cell death by repressing the metabolic stress UPR transcriptional network through binding to and inhibiting transcription of ATF3 and CHOP promoters, dependent on its deubiquitinating activity; Bap1 KO mice show enhanced sensitivity to tunicamycin-induced renal damage.","method":"ChIP, reporter assays, RNAi, Bap1 KO mice, metabolic stress assays (ROS, ATP measurements)","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — direct ChIP at ATF3/CHOP promoters, catalytic activity requirement shown, in vivo mouse validation","pmids":["28275095"],"is_preprint":false},{"year":2018,"finding":"BAP1 is a component of the DRED γ-globin gene repressor complex and maintains NCoR1 at sites in the β-globin locus through deubiquitinase activity; BAP1 inhibition in erythroid cells massively induces γ-globin synthesis.","method":"Co-IP, ChIP, BAP1 inhibition in erythroid cells, γ-globin expression assays","journal":"Genes & Development","confidence":"High","confidence_rationale":"Tier 2 — direct Co-IP demonstrating complex membership, ChIP at globin locus, functional BAP1 inhibition phenotype","pmids":["30463901"],"is_preprint":false},{"year":2018,"finding":"Truncated ASXL1 (gain-of-function frameshift mutant) increases BAP1 protein stability and enhances BAP1 recruitment to chromatin, promoting pro-leukemic transcriptional signatures; BAP1 catalytic inhibitors suppress truncated-ASXL1-driven leukemic gene expression and impair tumor progression in vivo.","method":"Biochemical screen for BAP1 inhibitors, western blot, ChIP-seq, in vivo leukemia models","journal":"Nature Cancer","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical screen with functional validation, ChIP-seq, in vivo tumor model with catalytic inhibitor","pmids":["35122023"],"is_preprint":false},{"year":2018,"finding":"Mutant ASXL1 (C-terminal truncation) increases BAP1's catalytic function via monoubiquitination of ASXL1-MT; the hyperactive ASXL1-MT/BAP1 complex drives myeloid leukaemogenesis by removing H2AK119 ubiquitination at posterior HOXA genes and IRF8, upregulating their expression.","method":"Co-IP, in vitro ubiquitination/deubiquitination assays, ChIP-seq (H2AK119ub), gene expression analysis, mouse leukemia models","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical reconstitution of ASXL1-MT/BAP1 activity, ChIP-seq, in vivo mouse model","pmids":["30013160"],"is_preprint":false},{"year":2019,"finding":"BAP1 promotes restart of hydroxyurea-induced stalled replication forks by recruiting INO80 to stalled forks; BAP1 depletion abrogates INO80 binding at stalled forks, increases RAD51 foci, reduces S-phase progression under replication stress, and causes hypersensitivity to HU, all rescued by INO80 re-expression.","method":"DNA fiber assay, iPOND/ChIP at stalled forks, immunofluorescence, INO80 rescue expression, HU sensitivity assays","journal":"The Biochemical Journal","confidence":"High","confidence_rationale":"Tier 2 — mechanistic rescue with INO80, direct ChIP at stressed forks, multiple orthogonal readouts","pmids":["31657441"],"is_preprint":false},{"year":2020,"finding":"BAP1 deubiquitinates and stabilizes PTEN protein; BAP1 physically binds PTEN, removes ubiquitin from PTEN to prevent proteasomal degradation, increases PTEN protein levels, and thereby inhibits AKT signaling and prostate cancer progression.","method":"Co-IP, in vitro deubiquitination assay, BAP1 knockdown/overexpression, AKT pathway readouts, xenograft rescue with PTEN re-expression","journal":"Molecular Oncology","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical DUB assay with PTEN substrate, reciprocal Co-IP, functional rescue in vivo","pmids":["33155366"],"is_preprint":false},{"year":2020,"finding":"BAP1 depletion causes proteasome-mediated degradation of BRCA1 in mesothelioma cells; BAP1 loss leads to spindle assembly checkpoint failure, centrosome amplification, and chromosome segregation errors (BRCA1-dependent), plus increased spindle length and astral microtubule growth due to loss of KIF18A and KIF18B kinesins (BRCA1-independent).","method":"BAP1 siRNA depletion, BRCA1 immunoblot with proteasome inhibitor rescue, immunofluorescence mitotic phenotypes, KIF18A/B re-expression rescue","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — mechanistic separation of BRCA1-dependent and independent pathways, direct rescue by KIF18A/B re-expression","pmids":["36550359"],"is_preprint":false},{"year":2020,"finding":"BAP1 depletion in pancreatic cancer leads to enhanced ubiquitin-dependent proteasomal degradation of the Hippo pathway tumor suppressor LATS, deregulating the Hippo pathway and promoting tumor progression.","method":"Conditional Bap1 knockout in KrasG12D pancreatic cancer mouse model, LATS ubiquitination/stability assays, Hippo pathway readouts","journal":"Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic in vivo model, pathway deregulation shown, but LATS as direct BAP1 substrate needs full biochemical confirmation","pmids":["31988076"],"is_preprint":false},{"year":2020,"finding":"BAP1 is glutamylated at Glu651 by TTLL5 and TTLL7, and this glutamylation accelerates BAP1 ubiquitination and proteasomal degradation; the carboxypeptidase CCP3 removes glutamylation from BAP1 to stabilize it, enhancing Hoxa1 expression and promoting HSC self-renewal.","method":"In vitro glutamylation/deglutamylation assays, ubiquitination assays, CCP3 KO mice, BAP1-E651A knock-in mice, gene expression analysis","journal":"The Journal of Experimental Medicine","confidence":"High","confidence_rationale":"Tier 1-2 — novel PTM characterized biochemically, specific residue mutant knock-in mouse, CCP3 KO phenotype validation","pmids":["31699823"],"is_preprint":false},{"year":2021,"finding":"BAP1 forms a trimeric protein complex with HMGB1 and HDAC1; reduced BAP1 levels cause increased ubiquitylation and degradation of HDAC1, leading to increased HMGB1 acetylation and its active secretion, which promotes mesothelial cell transformation.","method":"Co-IP (trimeric complex identification), ubiquitination assay for HDAC1, HMGB1 acetylation measurement, secretion assay, BAP1+/- patient serum analysis","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — trimeric complex characterized by Co-IP, mechanistic link between BAP1 levels, HDAC1 stability, HMGB1 acetylation demonstrated with patient validation","pmids":["34815344"],"is_preprint":false},{"year":2021,"finding":"BAP1 downregulation is required to trigger epithelial-mesenchymal transition (EMT) during trophoblast differentiation; this function depends on BAP1 binding to ASXL1/2 proteins to form the PR-DUB complex, as demonstrated by CRISPR knockout and overexpression in mouse and human trophoblast stem cells.","method":"CRISPR/Cas9 KO, BAP1 overexpression, EMT marker analysis, BAP1-ASXL1/2 interaction studies in trophoblast stem cells","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — clean CRISPR KO and OE in relevant cell type, ASXL binding requirement demonstrated, conserved in human cells","pmids":["34170818"],"is_preprint":false},{"year":2021,"finding":"BAP1 cell-intrinsically regulates B lymphocyte development by deubiquitinating histone H2AK119ub; Bap1 conditional deletion in B cells depletes large pre-B cells, transitional, and mature B cells, with broad transcriptional changes mapped by BAP1 ChIP-seq and H2AK119ub profiling.","method":"Bap1fl/fl mb1-Cre conditional KO mice, flow cytometry, RNA-seq, ChIP-seq (BAP1 binding, H2AK119ub)","journal":"Frontiers in Immunology","confidence":"High","confidence_rationale":"Tier 2 — clean conditional KO, ChIP-seq demonstrating direct BAP1 occupancy and H2AK119ub changes genome-wide","pmids":["33912157"],"is_preprint":false},{"year":2021,"finding":"BAP1 negatively regulates expression of TRAIL receptors DR4 and DR5 through direct interaction with the transcription factor YY1; BAP1 and YY1 are co-enriched at DR4/DR5 promoters by ChIP, and catalytic BAP1 mutant cannot repress DR4/DR5 promoter activity.","method":"Co-IP (BAP1-YY1), ChIP at DR4/DR5 promoters, reporter assays with WT and catalytic BAP1 mutant, YY1 siRNA knockdown, tissue microarrays","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, direct ChIP, catalytic mutant functional test, clinical tissue validation","pmids":["34597666"],"is_preprint":false},{"year":2022,"finding":"Transportin-1 (TNPO1/Karyopherin β2) targets an atypical C-terminal proline-tyrosine nuclear localization signal (PY-NLS) on BAP1 and serves as its primary nuclear transporter; TNPO1 binding dissociates dimeric BAP1 and sequesters monoubiquitination sites flanking the PY-NLS to counteract UBE2O-mediated cytoplasmic retention of BAP1.","method":"Biochemical binding assays, nuclear import assays, domain mutagenesis (PY-NLS), BAP1 dimerization analysis, UBE2O competition assay","journal":"The Journal of Cell Biology","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding mapped to specific NLS motif, mechanistic competition between TNPO1 and UBE2O demonstrated, nuclear import assay","pmids":["35446349"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structure of human BAP1 with the ASXL1 DEUBAD domain bound to a H2AK119Ub nucleosome reveals molecular interactions of BAP1 and ASXL1 with histones and DNA that restructure the nucleosome and establish specificity for H2AK119Ub; >50 cancer-associated mutations in BAP1 and ASXL1 are mapped to mechanistically explain dysregulation of H2AK119Ub deubiquitination.","method":"Cryo-EM structure determination, biochemical reconstitution, cancer mutation structure-function analysis, cellular deubiquitination assays","journal":"Science Advances","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure with biochemical and cellular validation, mechanistic explanation of cancer mutations","pmids":["37556531"],"is_preprint":false},{"year":2023,"finding":"In osteoclasts, BAP1 deubiquitinase activity regulates osteoclast function through metabolic reprogramming: BAP1 deficiency elevates H2Aub at the SLC7A11 promoter and upregulates SLC7A11 expression, redirecting mitochondrial metabolites from the TCA cycle and altering ROS levels, thereby arresting osteoclast cytoskeletal organization and bone resorption.","method":"Bap1 conditional KO in myeloid cells (LysM-Cre), cytoskeletal organization assays, H2Aub ChIP at SLC7A11 promoter, metabolic profiling","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined phenotype, direct ChIP demonstrating epigenetic mechanism, metabolic profiling","pmids":["37740028"],"is_preprint":false},{"year":2015,"finding":"BAP1 deubiquitinates and stabilizes MCRS1 (a centrosome component involved in spindle assembly), contributing to chromosome stability in renal cell carcinoma; BAP1 loss reduces MCRS1 levels and induces chromosomal instability.","method":"Co-IP, in vitro deubiquitination assay, chromosome stability assays, correlation in ccRCC tissue samples","journal":"Cancer Letters","confidence":"Medium","confidence_rationale":"Tier 2 — DUB assay and Co-IP, but single lab study","pmids":["26300492"],"is_preprint":false},{"year":2020,"finding":"BAP1 deubiquitinates and stabilizes DIDO1 (a centrosome component required for spindle assembly) through deubiquitination, thereby maintaining chromosome stability in renal cell carcinoma.","method":"Co-IP, in vitro deubiquitination assay, chromosome stability assays, correlation in ccRCC tissues","journal":"American Journal of Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — DUB assay, Co-IP, functional chromosome stability readout, single lab","pmids":["32509391"],"is_preprint":false},{"year":2020,"finding":"ASXL3 physically interacts with BRD4's extra-terminal (ET) domain via a novel BRD4-binding motif (BBM) and bridges BRD4 to the BAP1 complex; ASXL3 maintains chromatin occupancy of BRD4 at active enhancers in SCLC, and ASXL3 depletion causes genome-wide reduction of H3K27Ac and BRD4-dependent gene expression.","method":"Size exclusion chromatography, mass spectrometry, Co-IP, ChIP-seq (BRD4, H3K27Ac), RNA-seq, ASXL3 KO in SCLC cells","journal":"Genome Medicine","confidence":"High","confidence_rationale":"Tier 2 — direct interaction mapped biochemically, ChIP-seq, functional gene expression changes with KO","pmids":["32669118"],"is_preprint":false},{"year":2020,"finding":"C-terminally truncated ASXL1 loss of FOXK1/K2 interaction impairs the BAP1-ASXL1-FOXK1/K2 transcriptional network; wild-type ASXL1 interacts with FOXK1/K2 to regulate glucose metabolism, oxygen sensing, and JAK-STAT3 signaling pathway target genes via BAP1, and mutant ASXL1 dominantly inhibits this network.","method":"Co-IP (ASXL1-FOXK1/K2-BAP1), selective deletion of mutant allele, RNA-seq, gene expression rescue","journal":"Protein & Cell","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP of complex, allele-specific deletion, functional gene expression rescue; single lab","pmids":["32683582"],"is_preprint":false},{"year":2024,"finding":"BAP1 deubiquitinates MAFF transcription factor (removing K48-linked ubiquitin) and stabilizes it; stabilized MAFF upregulates DUSP5 expression, which inhibits ERK phosphorylation and suppresses colorectal cancer growth.","method":"DUB screening library, Co-IP, in vitro deubiquitination assay, MAFF knockdown/overexpression, ERK pathway readouts, xenograft models","journal":"European Journal of Cancer","confidence":"Medium","confidence_rationale":"Tier 1-2 — DUB assay, Co-IP, functional downstream pathway validation, in vivo model; single lab","pmids":["39151323"],"is_preprint":false},{"year":2024,"finding":"BAP1 protects against disulfidptosis by suppressing SLC7A11-mediated cystine uptake (via H2Aub deubiquitination at SLC7A11 promoter) and by maintaining NADPH levels; loss of BAP1 or overexpression of SLC7A11 promotes disulfidptosis under glucose starvation.","method":"Cell death inhibitor profiling, disulfide bond accumulation assays, SLC7A11 KO/overexpression, erastin treatment, NADP+/NADPH measurement","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — multiple cell death inhibitors and genetic manipulations, mechanistic link through SLC7A11; single lab","pmids":["39266549"],"is_preprint":false},{"year":2021,"finding":"BAP1 overexpression enhances P53 activity and stability by reducing proteasome-mediated P53 degradation; the transcription factor ATF2 regulates BAP1 expression by binding the BAP1 promoter, placing BAP1 in an ATF2-BAP1-P53 axis mediating neuronal apoptosis.","method":"Luciferase assay (ATF2 binding to BAP1 promoter), Co-IP, P53 ubiquitination/stability assays, BAP1 shRNA knockdown in mouse SAH model","journal":"Stroke","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase and Co-IP for upstream regulation, P53 stability mechanistic link, in vivo mouse model; single lab","pmids":["38965653"],"is_preprint":false}],"current_model":"BAP1 is a nuclear (and ER-localized) deubiquitinase whose primary chromatin substrate is H2AK119Ub; it is activated by ASXL1/2/3 DEUBAD domains and operates as the catalytic subunit of the Polycomb repressive deubiquitinase (PR-DUB) complex, where its specificity for H2AK119Ub over other nucleosomal ubiquitin sites is established by restructuring the nucleosome (as revealed by cryo-EM); beyond histones, BAP1 deubiquitinates and stabilizes multiple protein substrates including HCF-1, IP3R3 (at the ER to regulate Ca2+ flux and apoptosis), INO80 (to promote DNA replication fork progression), PTEN, KLF5, MCRS1, DIDO1, and MAFF; it represses SLC7A11 transcription via H2Aub removal to suppress cystine uptake and promote ferroptosis; its nuclear import is governed by transportin-1 targeting a PY-NLS, competing with UBE2O-mediated monoubiquitination; and it is regulated post-translationally by phosphorylation (required for DSB repair) and glutamylation at Glu651 (controlling its own stability in HSCs)."},"narrative":{"teleology":[{"year":2009,"claim":"Identifying HCF-1 as a direct BAP1 substrate established that BAP1 functions as a deubiquitinase for non-histone proteins with roles in cell proliferation, not solely as a chromatin modifier.","evidence":"Mass spectrometry, reciprocal Co-IP, in vitro DUB assay, and HBM-mutant functional analysis in human cells","pmids":["19815555"],"confidence":"High","gaps":["Whether HCF-1 deubiquitination is the primary mechanism of BAP1 tumor suppression was unresolved","Full repertoire of BAP1 substrates unknown"]},{"year":2010,"claim":"Mapping BAP1 inactivating mutations to the UCH catalytic domain in metastasizing uveal melanomas established that deubiquitinase activity is essential for BAP1's tumor-suppressive function.","evidence":"Exome sequencing of uveal melanomas with mutation mapping to the UCH domain","pmids":["21051595"],"confidence":"High","gaps":["The critical substrate(s) mediating tumor suppression were not identified","Whether catalytic activity is the sole tumor-suppressive mechanism was unclear"]},{"year":2012,"claim":"Demonstrating that HCF-1 binding and H2AK119Ub deubiquitination are separable BAP1 functions revealed that BAP1 tumor suppression involves multiple independent downstream pathways.","evidence":"Tumorgraft fractionation, HBM-mutant analysis distinguishing proliferation control from H2A DUB activity in renal cell carcinoma","pmids":["22683710"],"confidence":"High","gaps":["Relative contributions of H2A DUB versus HCF-1 DUB to tumor suppression in different cancer types unclear"]},{"year":2013,"claim":"Showing that BAP1 is recruited to DSB sites and that both catalytic activity and IR-induced phosphorylation are required for HR-mediated repair placed BAP1 in the DNA damage response and revealed phosphorylation as a regulatory input.","evidence":"DT40 knockout, immunofluorescence foci, ChIP at I-SceI sites, phospho-site mutagenesis","pmids":["24347639"],"confidence":"High","gaps":["Identity of the kinase(s) phosphorylating BAP1 after IR not determined","Precise DUB substrate at DSBs not identified"]},{"year":2014,"claim":"Identification of INO80 as a BAP1 substrate that is stabilized by deubiquitination and recruited to replication forks extended BAP1 function from transcription and repair to DNA replication fork progression.","evidence":"Co-IP, in vitro DUB assay, ChIP at replication forks in BAP1-defective cancer cells","pmids":["25283999"],"confidence":"High","gaps":["How BAP1 senses replication stress to recruit INO80 was not defined"]},{"year":2015,"claim":"Biochemical reconstitution showing that ASXL1/2 DEUBAD domains form a composite ubiquitin-binding interface with BAP1 and activate H2AK119Ub-specific (but not H2AK13/15Ub) deubiquitination defined the PR-DUB activation mechanism and its substrate selectivity.","evidence":"In vitro reconstitution with purified proteins, nucleosome-binding assays, domain deletion/mutation analysis","pmids":["26739236","26416890"],"confidence":"High","gaps":["Structural basis for selectivity between H2AK119Ub and H2AK13/15Ub not resolved at atomic level"]},{"year":2015,"claim":"Genetic epistasis between Bap1 loss and Ezh2 deletion in mice revealed that BAP1 indirectly opposes PRC2-mediated H3K27me3 through effects on H4K20me1 and EZH2 levels, placing BAP1 in a Polycomb regulatory circuit.","evidence":"Bap1/Ezh2 double conditional KO mice, ChIP-seq for H3K27me3 and H4K20me1, pharmacological EZH2 inhibition","pmids":["26437366"],"confidence":"High","gaps":["Whether BAP1 directly or indirectly controls EZH2 expression levels was not resolved"]},{"year":2017,"claim":"Discovery that BAP1 localizes to the ER where it deubiquitinates and stabilizes IP3R3 to promote Ca²⁺-mediated apoptosis established a non-chromatin tumor-suppressive mechanism operating through calcium signaling.","evidence":"Subcellular fractionation, ER imaging, DUB assay, Ca²⁺ flux measurement, BAP1+/− patient-derived cells","pmids":["28614305"],"confidence":"High","gaps":["How BAP1 partitions between nucleus and ER was not mechanistically explained","ER-specific interactors beyond IP3R3 not catalogued"]},{"year":2018,"claim":"Demonstration that BAP1 represses SLC7A11 by removing H2Aub at its promoter, thereby restricting cystine uptake and sensitizing cells to ferroptosis, linked BAP1's epigenetic activity to a specific regulated cell death pathway.","evidence":"ChIP-seq for H2Aub, RNA-seq, ferroptosis and lipid peroxidation assays, catalytic mutant analysis, xenograft models","pmids":["30202049"],"confidence":"High","gaps":["Whether ferroptosis contributes to BAP1's tumor-suppressive activity in patients was not established"]},{"year":2018,"claim":"Finding that truncated ASXL1 gain-of-function mutants increase BAP1 stability, chromatin recruitment, and H2AK119Ub removal at HOXA loci to drive myeloid leukemogenesis revealed how oncogenic ASXL1 mutations hijack normal PR-DUB activity.","evidence":"Co-IP, ChIP-seq for H2AK119ub, in vivo leukemia models, BAP1 catalytic inhibitor validation","pmids":["30013160","35122023"],"confidence":"High","gaps":["Whether BAP1 catalytic inhibitors are therapeutically viable in ASXL1-mutant leukemia patients not tested clinically"]},{"year":2020,"claim":"Identification of glutamylation at Glu651 as a degradation signal for BAP1—installed by TTLL5/7 and removed by CCP3—revealed a novel post-translational regulatory layer controlling BAP1 stability in hematopoietic stem cells.","evidence":"In vitro glutamylation/deglutamylation assays, BAP1-E651A knock-in mice, CCP3 KO mice","pmids":["31699823"],"confidence":"High","gaps":["Whether glutamylation regulates BAP1 in non-hematopoietic tissues is unknown","Identity of the E3 ligase triggered by glutamylation not determined"]},{"year":2020,"claim":"Expanding BAP1's substrate repertoire to include PTEN established a direct link between BAP1 deubiquitinase activity and suppression of PI3K-AKT signaling in cancer.","evidence":"Reciprocal Co-IP, in vitro DUB assay on PTEN, AKT pathway readouts, xenograft rescue with PTEN re-expression","pmids":["33155366"],"confidence":"High","gaps":["Whether PTEN stabilization is relevant across all BAP1-mutant cancer types or tissue-specific"]},{"year":2022,"claim":"Mapping transportin-1 recognition of BAP1's PY-NLS and its competition with UBE2O-mediated monoubiquitination explained how BAP1 nuclear-cytoplasmic distribution is actively regulated, resolving the question of how BAP1 partitions between nuclear and ER functions.","evidence":"Biochemical binding assays, nuclear import assays, PY-NLS mutagenesis, UBE2O competition assay","pmids":["35446349"],"confidence":"High","gaps":["Signal(s) that shift the TNPO1–UBE2O balance in physiological or stress contexts not identified"]},{"year":2023,"claim":"The cryo-EM structure of BAP1–ASXL1 DEUBAD bound to H2AK119Ub nucleosome resolved at atomic detail how PR-DUB achieves substrate specificity by restructuring the nucleosome, and structurally rationalized >50 cancer mutations.","evidence":"Cryo-EM structure determination, biochemical reconstitution, cellular DUB assays, cancer mutation mapping","pmids":["37556531"],"confidence":"High","gaps":["Structures with ASXL2 or ASXL3 not determined","How the PR-DUB complex is recruited to specific genomic loci rather than acting genome-wide remains unclear"]},{"year":null,"claim":"How BAP1 is targeted to specific genomic loci (beyond FoxK2- and YY1-mediated recruitment) to achieve gene-selective H2AK119Ub removal, and how its nuclear versus ER functions are coordinately regulated under physiological conditions, remain major open questions.","evidence":"","pmids":[],"confidence":"High","gaps":["Genome-wide determinants of BAP1 locus specificity not systematically defined","Relative contributions of chromatin vs. ER-based tumor suppression not quantified in vivo","Whether BAP1 catalytic inhibitors represent viable cancer therapeutics is untested clinically"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,6,7,9,10,11,17,26,28,29,32]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,7,9,10,17,28,29,32]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[9,11,26]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,3,5,9,11,23,25,26]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[3,9,26]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[2,5,8,9,11,15,23,26,27]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[3,16]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[4,16]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,11,13,24]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,11,33]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[7,18]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,14,15]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[23]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[17,19]}],"complexes":["PR-DUB (Polycomb repressive deubiquitinase)","DRED γ-globin repressor complex","BAP1-HMGB1-HDAC1 complex"],"partners":["ASXL1","ASXL2","ASXL3","HCF1","FOXK2","INO80","TNPO1","YY1"],"other_free_text":[]},"mechanistic_narrative":"BAP1 is a nuclear deubiquitinase that serves as the catalytic subunit of the Polycomb repressive deubiquitinase (PR-DUB) complex, coupling histone H2AK119Ub removal with transcriptional regulation, DNA repair, replication fork progression, calcium-mediated apoptosis, and ferroptosis. Activated by ASXL1/2/3 DEUBAD domains that generate a composite ubiquitin-binding interface conferring specificity for H2AK119Ub over DNA-damage-associated H2AK13/15Ub, BAP1 restructures the nucleosome to access its substrate, as revealed by cryo-EM [PMID:37556531, PMID:26739236]. Beyond histones, BAP1 deubiquitinates and stabilizes diverse protein substrates—including HCF-1, IP3R3 at the ER (promoting Ca²⁺ flux and apoptosis), INO80 (enabling replication fork restart), PTEN, KLF5, and HDAC1—thereby integrating chromatin remodeling with cell proliferation, genomic stability, and metabolic control [PMID:19815555, PMID:28614305, PMID:25283999, PMID:33155366, PMID:26419610, PMID:34815344]. BAP1 represses SLC7A11 transcription through H2Aub removal to restrict cystine uptake and sensitize cells to ferroptosis, and its nuclear import is governed by transportin-1 recognition of a C-terminal PY-NLS that competes with UBE2O-mediated cytoplasmic retention, while its stability is modulated by glutamylation at Glu651 [PMID:30202049, PMID:35446349, PMID:31699823]."},"prefetch_data":{"uniprot":{"accession":"Q92560","full_name":"Ubiquitin carboxyl-terminal hydrolase BAP1","aliases":["BRCA1-associated protein 1","Cerebral protein 6"],"length_aa":729,"mass_kda":80.4,"function":"Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1 (PubMed:12485996, PubMed:18757409, PubMed:20436459, PubMed:25451922, PubMed:35051358). Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1) (PubMed:20436459, PubMed:25451922, PubMed:30664650, PubMed:35051358). Does not deubiquitinate monoubiquitinated histone H2B (PubMed:20436459, PubMed:30664650). The PR-DUB complex is an epigenetic regulator of gene expression and acts as a transcriptional coactivator, affecting genes involved in development, cell communication, signaling, cell proliferation and cell viability (PubMed:20805357, PubMed:30664650, PubMed:36180891). Antagonizes PRC1 mediated H2AK119ub1 monoubiquitination (PubMed:30664650). As part of the PR-DUB complex, associates with chromatin enriched in histone marks H3K4me1, H3K4me3, and H3K27Ac, but not in H3K27me3 (PubMed:36180891). Recruited to specific gene-regulatory regions by YY1 (PubMed:20805357). Acts as a regulator of cell growth by mediating deubiquitination of HCFC1 N-terminal and C-terminal chains, with some specificity toward 'Lys-48'-linked polyubiquitin chains compared to 'Lys-63'-linked polyubiquitin chains (PubMed:19188440, PubMed:19815555). Deubiquitination of HCFC1 does not lead to increase stability of HCFC1 (PubMed:19188440, PubMed:19815555). Interferes with the BRCA1 and BARD1 heterodimer activity by inhibiting their ability to mediate ubiquitination and autoubiquitination (PubMed:19117993). It however does not mediate deubiquitination of BRCA1 and BARD1 (PubMed:19117993). Able to mediate autodeubiquitination via intramolecular interactions to counteract monoubiquitination at the nuclear localization signal (NLS), thereby protecting it from cytoplasmic sequestration (PubMed:24703950). Negatively regulates epithelial-mesenchymal transition (EMT) of trophoblast stem cells during placental development by regulating genes involved in epithelial cell integrity, cell adhesion and cytoskeletal organization (PubMed:34170818)","subcellular_location":"Cytoplasm; Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/Q92560/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BAP1","classification":"Not Classified","n_dependent_lines":682,"n_total_lines":1208,"dependency_fraction":0.5645695364238411},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BAP1","total_profiled":1310},"omim":[{"mim_id":"619762","title":"KURY-ISIDOR SYNDROME; KURIS","url":"https://www.omim.org/entry/619762"},{"mim_id":"619458","title":"METHYL-CpG-BINDING DOMAIN PROTEIN 6; MBD6","url":"https://www.omim.org/entry/619458"},{"mim_id":"618813","title":"TUBULIN TYROSINE LIGASE-LIKE 7; TTLL7","url":"https://www.omim.org/entry/618813"},{"mim_id":"617649","title":"UBIQUITIN-CONJUGATING ENZYME E2 O; UBE2O","url":"https://www.omim.org/entry/617649"},{"mim_id":"617346","title":"ATP/GTP-BINDING PROTEIN-LIKE 3; AGBL3","url":"https://www.omim.org/entry/617346"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BAP1"},"hgnc":{"alias_symbol":["hucep-6","KIAA0272","UCHL2"],"prev_symbol":[]},"alphafold":{"accession":"Q96QZ7","domains":[{"cath_id":"2.30.42.10","chopping":"12-53_60-142_192-213","consensus_level":"high","plddt":82.7526,"start":12,"end":213},{"cath_id":"2.20.70","chopping":"364-401","consensus_level":"medium","plddt":79.8232,"start":364,"end":401},{"cath_id":"2.30.42.10","chopping":"464-565","consensus_level":"high","plddt":87.1854,"start":464,"end":565},{"cath_id":"2.30.42.10","chopping":"641-722","consensus_level":"high","plddt":84.7895,"start":641,"end":722},{"cath_id":"2.30.42.10","chopping":"838-925","consensus_level":"medium","plddt":89.7289,"start":838,"end":925},{"cath_id":"2.30.42.10","chopping":"998-1017_1034-1092","consensus_level":"medium","plddt":84.7994,"start":998,"end":1092},{"cath_id":"2.30.42.10","chopping":"1152-1232","consensus_level":"high","plddt":91.4384,"start":1152,"end":1232}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96QZ7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96QZ7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96QZ7-F1-predicted_aligned_error_v6.png","plddt_mean":59.91},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BAP1","jax_strain_url":"https://www.jax.org/strain/search?query=BAP1"},"sequence":{"accession":"Q96QZ7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96QZ7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96QZ7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96QZ7"}},"corpus_meta":[{"pmid":"21051595","id":"PMC_21051595","title":"Frequent mutation of BAP1 in metastasizing uveal melanomas.","date":"2010","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21051595","citation_count":1150,"is_preprint":false},{"pmid":"30202049","id":"PMC_30202049","title":"BAP1 links metabolic regulation of ferroptosis to tumour suppression.","date":"2018","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30202049","citation_count":830,"is_preprint":false},{"pmid":"22683710","id":"PMC_22683710","title":"BAP1 loss defines a new class of renal cell carcinoma.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22683710","citation_count":768,"is_preprint":false},{"pmid":"21941004","id":"PMC_21941004","title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.","date":"2011","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21941004","citation_count":362,"is_preprint":false},{"pmid":"28614305","id":"PMC_28614305","title":"BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28614305","citation_count":330,"is_preprint":false},{"pmid":"24347639","id":"PMC_24347639","title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24347639","citation_count":305,"is_preprint":false},{"pmid":"26437366","id":"PMC_26437366","title":"Loss of BAP1 function leads to EZH2-dependent transformation.","date":"2015","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26437366","citation_count":297,"is_preprint":false},{"pmid":"22935333","id":"PMC_22935333","title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.","date":"2012","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22935333","citation_count":239,"is_preprint":false},{"pmid":"32690542","id":"PMC_32690542","title":"Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.","date":"2020","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/32690542","citation_count":231,"is_preprint":false},{"pmid":"19815555","id":"PMC_19815555","title":"The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19815555","citation_count":223,"is_preprint":false},{"pmid":"23277170","id":"PMC_23277170","title":"Tumours associated with BAP1 mutations.","date":"2013","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23277170","citation_count":222,"is_preprint":false},{"pmid":"23684012","id":"PMC_23684012","title":"Germline BAP1 mutations predispose to renal cell carcinomas.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23684012","citation_count":220,"is_preprint":false},{"pmid":"30517737","id":"PMC_30517737","title":"Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.","date":"2018","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/30517737","citation_count":203,"is_preprint":false},{"pmid":"26419610","id":"PMC_26419610","title":"BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26419610","citation_count":179,"is_preprint":false},{"pmid":"26739236","id":"PMC_26739236","title":"BAP1/ASXL1 recruitment and activation for H2A deubiquitination.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26739236","citation_count":165,"is_preprint":false},{"pmid":"28170043","id":"PMC_28170043","title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.","date":"2017","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28170043","citation_count":152,"is_preprint":false},{"pmid":"28473526","id":"PMC_28473526","title":"Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.","date":"2017","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/28473526","citation_count":144,"is_preprint":false},{"pmid":"32877777","id":"PMC_32877777","title":"BAP1: Not just a BRCA1-associated protein.","date":"2020","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32877777","citation_count":139,"is_preprint":false},{"pmid":"33462414","id":"PMC_33462414","title":"Roles and mechanisms of BAP1 deubiquitinase in tumor suppression.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/33462414","citation_count":134,"is_preprint":false},{"pmid":"24928783","id":"PMC_24928783","title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24928783","citation_count":115,"is_preprint":false},{"pmid":"26416890","id":"PMC_26416890","title":"The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26416890","citation_count":113,"is_preprint":false},{"pmid":"30013160","id":"PMC_30013160","title":"Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30013160","citation_count":109,"is_preprint":false},{"pmid":"25938359","id":"PMC_25938359","title":"Loss of expression of BAP1 predicts longer survival in mesothelioma.","date":"2015","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25938359","citation_count":103,"is_preprint":false},{"pmid":"25283999","id":"PMC_25283999","title":"Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25283999","citation_count":103,"is_preprint":false},{"pmid":"21484256","id":"PMC_21484256","title":"An emerging model for BAP1's role in regulating cell cycle progression.","date":"2011","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/21484256","citation_count":102,"is_preprint":false},{"pmid":"23867514","id":"PMC_23867514","title":"PBRM1 and BAP1 as novel targets for renal cell carcinoma.","date":"2013","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/23867514","citation_count":98,"is_preprint":false},{"pmid":"17631528","id":"PMC_17631528","title":"The Arabidopsis BAP1 and BAP2 genes are general inhibitors of programmed cell death.","date":"2007","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17631528","citation_count":94,"is_preprint":false},{"pmid":"28793149","id":"PMC_28793149","title":"Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.","date":"2017","source":"JAMA dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28793149","citation_count":88,"is_preprint":false},{"pmid":"28409567","id":"PMC_28409567","title":"SF3B1 and BAP1 mutations in blue nevus-like melanoma.","date":"2017","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/28409567","citation_count":85,"is_preprint":false},{"pmid":"25080371","id":"PMC_25080371","title":"Germline BAP1 mutations predispose also to multiple basal cell carcinomas.","date":"2014","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25080371","citation_count":83,"is_preprint":false},{"pmid":"28275095","id":"PMC_28275095","title":"BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28275095","citation_count":82,"is_preprint":false},{"pmid":"29988936","id":"PMC_29988936","title":"Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma.","date":"2018","source":"Journal of current ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/29988936","citation_count":81,"is_preprint":false},{"pmid":"26900815","id":"PMC_26900815","title":"BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.","date":"2016","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26900815","citation_count":81,"is_preprint":false},{"pmid":"27235536","id":"PMC_27235536","title":"Gene of the month: BAP1.","date":"2016","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27235536","citation_count":76,"is_preprint":false},{"pmid":"25451922","id":"PMC_25451922","title":"BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the ubiquitin-mediated activation of FoxK2 target genes.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25451922","citation_count":74,"is_preprint":false},{"pmid":"23147254","id":"PMC_23147254","title":"The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.","date":"2012","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/23147254","citation_count":72,"is_preprint":false},{"pmid":"28122578","id":"PMC_28122578","title":"BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma.","date":"2017","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28122578","citation_count":71,"is_preprint":false},{"pmid":"35122023","id":"PMC_35122023","title":"Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.","date":"2021","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35122023","citation_count":68,"is_preprint":false},{"pmid":"27859460","id":"PMC_27859460","title":"Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma.","date":"2017","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/27859460","citation_count":67,"is_preprint":false},{"pmid":"27181379","id":"PMC_27181379","title":"CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/27181379","citation_count":61,"is_preprint":false},{"pmid":"28713672","id":"PMC_28713672","title":"BAP1, a tumor suppressor gene driving malignant mesothelioma.","date":"2017","source":"Translational lung cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28713672","citation_count":56,"is_preprint":false},{"pmid":"31233225","id":"PMC_31233225","title":"BRCA1-associated protein (BAP1)-inactivated melanocytic tumors.","date":"2019","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31233225","citation_count":53,"is_preprint":false},{"pmid":"32669118","id":"PMC_32669118","title":"ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.","date":"2020","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32669118","citation_count":51,"is_preprint":false},{"pmid":"35459788","id":"PMC_35459788","title":"Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.","date":"2022","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/35459788","citation_count":50,"is_preprint":false},{"pmid":"26765459","id":"PMC_26765459","title":"Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma.","date":"2016","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26765459","citation_count":50,"is_preprint":false},{"pmid":"31285370","id":"PMC_31285370","title":"BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31285370","citation_count":49,"is_preprint":false},{"pmid":"23977234","id":"PMC_23977234","title":"A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23977234","citation_count":47,"is_preprint":false},{"pmid":"33210135","id":"PMC_33210135","title":"BAP1-Mutated Clear Cell Renal Cell Carcinoma.","date":"2021","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33210135","citation_count":46,"is_preprint":false},{"pmid":"32271879","id":"PMC_32271879","title":"Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice.","date":"2020","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32271879","citation_count":46,"is_preprint":false},{"pmid":"33446574","id":"PMC_33446574","title":"Roles of the BAP1 Tumor Suppressor in Cell Metabolism.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33446574","citation_count":45,"is_preprint":false},{"pmid":"33903674","id":"PMC_33903674","title":"Estimation of the timing of BAP1 mutation in uveal melanoma progression.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33903674","citation_count":45,"is_preprint":false},{"pmid":"37556531","id":"PMC_37556531","title":"Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37556531","citation_count":41,"is_preprint":false},{"pmid":"37607989","id":"PMC_37607989","title":"Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome.","date":"2023","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/37607989","citation_count":41,"is_preprint":false},{"pmid":"32206571","id":"PMC_32206571","title":"BAP1: role in carcinogenesis and clinical implications.","date":"2020","source":"Translational lung cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32206571","citation_count":40,"is_preprint":false},{"pmid":"26300492","id":"PMC_26300492","title":"Stabilization of MCRS1 by BAP1 prevents chromosome instability in renal cell carcinoma.","date":"2015","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26300492","citation_count":39,"is_preprint":false},{"pmid":"34170818","id":"PMC_34170818","title":"BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition during trophoblast differentiation and invasion.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34170818","citation_count":39,"is_preprint":false},{"pmid":"26885612","id":"PMC_26885612","title":"BAP1 suppresses lung cancer progression and is inhibited by miR-31.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26885612","citation_count":36,"is_preprint":false},{"pmid":"32185138","id":"PMC_32185138","title":"Identifying BAP1 Mutations in Clear-Cell Renal Cell Carcinoma by CT Radiomics: Preliminary Findings.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32185138","citation_count":36,"is_preprint":false},{"pmid":"33155366","id":"PMC_33155366","title":"BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33155366","citation_count":35,"is_preprint":false},{"pmid":"28062663","id":"PMC_28062663","title":"A population-based analysis of germline BAP1 mutations in melanoma.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28062663","citation_count":34,"is_preprint":false},{"pmid":"27114369","id":"PMC_27114369","title":"Loss of expression of BAP1 is very rare in non-small cell lung carcinoma.","date":"2016","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27114369","citation_count":33,"is_preprint":false},{"pmid":"25687217","id":"PMC_25687217","title":"Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients.","date":"2015","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25687217","citation_count":32,"is_preprint":false},{"pmid":"32371459","id":"PMC_32371459","title":"CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32371459","citation_count":31,"is_preprint":false},{"pmid":"30463901","id":"PMC_30463901","title":"BAP1 regulation of the key adaptor protein NCoR1 is critical for γ-globin gene repression.","date":"2018","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/30463901","citation_count":31,"is_preprint":false},{"pmid":"35932824","id":"PMC_35932824","title":"The expanding role of BAP1 in clear cell renal cell carcinoma.","date":"2022","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35932824","citation_count":29,"is_preprint":false},{"pmid":"32683582","id":"PMC_32683582","title":"Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.","date":"2020","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/32683582","citation_count":29,"is_preprint":false},{"pmid":"31657441","id":"PMC_31657441","title":"BAP1 promotes stalled fork restart and cell survival via INO80 in response to replication stress.","date":"2019","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/31657441","citation_count":28,"is_preprint":false},{"pmid":"34815344","id":"PMC_34815344","title":"BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene × environment interaction with asbestos.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34815344","citation_count":28,"is_preprint":false},{"pmid":"31988076","id":"PMC_31988076","title":"The Tumor Suppressor BAP1 Regulates the Hippo Pathway in Pancreatic Ductal Adenocarcinoma.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31988076","citation_count":27,"is_preprint":false},{"pmid":"37740028","id":"PMC_37740028","title":"BAP1 promotes osteoclast function by metabolic reprogramming.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37740028","citation_count":24,"is_preprint":false},{"pmid":"33516665","id":"PMC_33516665","title":"BAP1 antagonizes WWP1-mediated transcription factor KLF5 ubiquitination and inhibits autophagy to promote melanoma progression.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33516665","citation_count":24,"is_preprint":false},{"pmid":"26774355","id":"PMC_26774355","title":"A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer.","date":"2015","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26774355","citation_count":23,"is_preprint":false},{"pmid":"34706158","id":"PMC_34706158","title":"Co-occurrence of BAP1 and SF3B1 mutations in uveal melanoma induces cellular senescence.","date":"2021","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34706158","citation_count":22,"is_preprint":false},{"pmid":"31058963","id":"PMC_31058963","title":"Population-based analysis of BAP1 germline variations in patients with uveal melanoma.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31058963","citation_count":21,"is_preprint":false},{"pmid":"33316260","id":"PMC_33316260","title":"Uveal Melanoma in BAP1 Tumor Predisposition Syndrome: Estimation of Risk.","date":"2020","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/33316260","citation_count":21,"is_preprint":false},{"pmid":"34857909","id":"PMC_34857909","title":"Novel insights into the BAP1-inactivated melanocytic tumor.","date":"2021","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/34857909","citation_count":20,"is_preprint":false},{"pmid":"35426938","id":"PMC_35426938","title":"Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal Melanoma.","date":"2022","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/35426938","citation_count":20,"is_preprint":false},{"pmid":"29802871","id":"PMC_29802871","title":"The diagnostic role of BAP1 in serous effusions.","date":"2018","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29802871","citation_count":20,"is_preprint":false},{"pmid":"31159579","id":"PMC_31159579","title":"BAP1 in solid tumors.","date":"2019","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31159579","citation_count":19,"is_preprint":false},{"pmid":"35833822","id":"PMC_35833822","title":"LncRNA NEAT1 promoted MPP+‑induced ferroptosis via regulating miR‑150‑5p/BAP1 pathway in SK‑N‑SH cells.","date":"2022","source":"Acta neurobiologiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/35833822","citation_count":19,"is_preprint":false},{"pmid":"38150154","id":"PMC_38150154","title":"ITGB2-ICAM1 axis promotes liver metastasis in BAP1-mutated uveal melanoma with retained hypoxia and ECM signatures.","date":"2023","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/38150154","citation_count":17,"is_preprint":false},{"pmid":"39266549","id":"PMC_39266549","title":"Tumor suppressor BAP1 suppresses disulfidptosis through the regulation of SLC7A11 and NADPH levels.","date":"2024","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/39266549","citation_count":17,"is_preprint":false},{"pmid":"36657447","id":"PMC_36657447","title":"Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.","date":"2023","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36657447","citation_count":17,"is_preprint":false},{"pmid":"29787736","id":"PMC_29787736","title":"G-quadruplexes in the BAP1 promoter positively regulate its expression.","date":"2018","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29787736","citation_count":17,"is_preprint":false},{"pmid":"36318367","id":"PMC_36318367","title":"BAP1 in cancer: epigenetic stability and genome integrity.","date":"2022","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36318367","citation_count":16,"is_preprint":false},{"pmid":"36292588","id":"PMC_36292588","title":"Intrinsic Disorder in BAP1 and Its Association with Uveal Melanoma.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36292588","citation_count":16,"is_preprint":false},{"pmid":"31699823","id":"PMC_31699823","title":"Glutamylation of deubiquitinase BAP1 controls self-renewal of hematopoietic stem cells and hematopoiesis.","date":"2020","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31699823","citation_count":16,"is_preprint":false},{"pmid":"34347929","id":"PMC_34347929","title":"The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.","date":"2021","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/34347929","citation_count":15,"is_preprint":false},{"pmid":"32509391","id":"PMC_32509391","title":"BAP1 maintains chromosome stability by stabilizing DIDO1 in renal cell carcinoma.","date":"2020","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32509391","citation_count":15,"is_preprint":false},{"pmid":"33800007","id":"PMC_33800007","title":"Intratumor Heterogeneity in Uveal Melanoma BAP-1 Expression.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33800007","citation_count":15,"is_preprint":false},{"pmid":"33529461","id":"PMC_33529461","title":"BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.","date":"2021","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/33529461","citation_count":14,"is_preprint":false},{"pmid":"33866194","id":"PMC_33866194","title":"The spectrum of tumors harboring BAP1 gene alterations.","date":"2021","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33866194","citation_count":14,"is_preprint":false},{"pmid":"35046531","id":"PMC_35046531","title":"Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35046531","citation_count":14,"is_preprint":false},{"pmid":"35317997","id":"PMC_35317997","title":"Impacts of Cancer-associated Mutations on the Structure-Activity Relationship of BAP1.","date":"2022","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35317997","citation_count":14,"is_preprint":false},{"pmid":"35446349","id":"PMC_35446349","title":"Tumor suppressor BAP1 nuclear import is governed by transportin-1.","date":"2022","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35446349","citation_count":13,"is_preprint":false},{"pmid":"33912157","id":"PMC_33912157","title":"Regulation of B Lymphocyte Development by Histone H2A Deubiquitinase BAP1.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33912157","citation_count":13,"is_preprint":false},{"pmid":"38965653","id":"PMC_38965653","title":"ATF2/BAP1 Axis Mediates Neuronal Apoptosis After Subarachnoid Hemorrhage via P53 Pathway.","date":"2024","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/38965653","citation_count":12,"is_preprint":false},{"pmid":"39151323","id":"PMC_39151323","title":"BAP1-mediated MAFF deubiquitylation regulates tumor growth and is associated with adverse outcomes in colorectal cancer.","date":"2024","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/39151323","citation_count":12,"is_preprint":false},{"pmid":"34597666","id":"PMC_34597666","title":"BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34597666","citation_count":12,"is_preprint":false},{"pmid":"36550359","id":"PMC_36550359","title":"BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36550359","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48594,"output_tokens":8593,"usd":0.137339},"stage2":{"model":"claude-opus-4-6","input_tokens":12365,"output_tokens":3891,"usd":0.23865},"total_usd":0.375989,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"BAP1 contains a ubiquitin carboxyl-terminal hydrolase (UCH) domain, and inactivating mutations including those affecting this UCH domain are found in metastasizing uveal melanomas, implicating BAP1 deubiquitinase activity in tumor suppression.\",\n      \"method\": \"Exome capture and massively parallel sequencing; mutation mapping to functional domain\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational study, replicated across many subsequent labs, mutations directly map to UCH catalytic domain\",\n      \"pmids\": [\"21051595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BAP1 interacts with and deubiquitinates host cell factor-1 (HCF-1) via a dedicated HCF-1 binding motif (HBM), and this interaction is required for BAP1-mediated cell proliferation regulation; HCF-1N is modified with Lys-48-linked polyubiquitin on its Kelch domain, which BAP1 removes.\",\n      \"method\": \"Mass spectrometry of co-purified proteins, Co-IP, in vitro deubiquitination assay, RNAi, dominant-negative overexpression\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal Co-IP, biochemical DUB assay, functional rescue with HBM mutant, replicated by subsequent studies\",\n      \"pmids\": [\"19815555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BAP1 co-fractionates with and binds HCF-1 in renal cell carcinoma tumorgrafts; mutations disrupting the HCF-1 binding motif impair BAP1-mediated suppression of cell proliferation but not deubiquitination of H2AK119ub1, indicating separable functions.\",\n      \"method\": \"Tumorgraft fractionation, Co-IP, cell proliferation assays, H2AK119ub1 deubiquitination assay, domain mutation analysis\",\n      \"journal\": \"Nature Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in primary tumor material, functional separation of HCF-1 binding from H2A DUB activity\",\n      \"pmids\": [\"22683710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BAP1 is required for efficient assembly of homologous recombination factors BRCA1 and RAD51 at ionizing radiation-induced foci; BAP1 is recruited to DSB sites, and both its catalytic activity and IR-induced phosphorylation at six sites are critical for DSB repair by HR.\",\n      \"method\": \"RNAi screen, DT40 knockout cells, immunofluorescence foci assay, ChIP at I-SceI DSB site, phosphorylation site mutagenesis\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple phenotypic readouts, active-site and phospho-site mutagenesis, direct chromatin recruitment assay\",\n      \"pmids\": [\"24347639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BAP1 deubiquitinates and stabilizes INO80 (catalytic ATPase of the INO80 chromatin-remodelling complex) and recruits it to replication forks via ubiquitinated H2A, promoting replication fork progression during normal DNA synthesis.\",\n      \"method\": \"Co-IP, in vitro deubiquitination assay, ChIP at replication forks, BAP1-defective cancer cell lines, mouse embryo Ino80 knockout\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical DUB assay, direct ChIP at forks, genetic validation in BAP1-defective cancer cells and mouse embryos\",\n      \"pmids\": [\"25283999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BAP1 acts as a deubiquitinase for histone H2A and is recruited to FoxK2 target gene promoters through an interaction with the forkhead-associated domain of FoxK2 (which binds phospho-Thr493 on BAP1); BAP1 bridges FoxK2 and HCF-1 in a ternary complex and represses FoxK2 target genes in opposition to the Ring1B-Bmi1 E3 ligase.\",\n      \"method\": \"ChIP, Co-IP, reporter assays, phospho-specific interaction mapping, RNAi knockdown\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, specific phospho-residue mapped, functional epistasis with Ring1B-Bmi1\",\n      \"pmids\": [\"25451922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BAP1 forms two mutually exclusive complexes with ASXL1 and ASXL2 via their ASXM domains interacting with BAP1's C-terminal domain (CTD); these interactions generate a composite ubiquitin-binding interface (CUBI) required for H2AK119 deubiquitination, and ASXL2 interaction also regulates cell senescence.\",\n      \"method\": \"Co-IP, in vitro deubiquitination assay, cancer-associated mutation analysis, cell proliferation and senescence assays\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical reconstitution of DUB activity, structural domain mapping, cancer mutation validation with multiple orthogonal methods\",\n      \"pmids\": [\"26416890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BAP1 acts as a bona fide deubiquitinase for KLF5 transcription factor in breast cancer cells, directly interacting with KLF5 and stabilizing it by removing ubiquitin; KLF5 is a component of the BAP1/HCF-1 complex, which promotes cell cycle progression partly by inhibiting p27 expression.\",\n      \"method\": \"Genome-wide siRNA DUB screen, Co-IP, in vitro deubiquitination assay, rescue experiments with KLF5 re-expression, xenograft models\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — systematic screen confirmed by biochemical DUB assay, functional rescue in vivo\",\n      \"pmids\": [\"26419610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Loss of BAP1 results in decreased H4K20 monomethylation (H4K20me1) and increased H3K27me3 via upregulation of EZH2; conditional co-deletion of Bap1 and Ezh2 in mice abrogates myeloid progenitor expansion caused by Bap1 loss alone, placing BAP1 upstream of the EZH2/PRC2 pathway.\",\n      \"method\": \"Mouse conditional knockout (Bap1/Ezh2 double KO), ChIP-seq (H3K27me3, H4K20me1), pharmacological EZH2 inhibition\",\n      \"journal\": \"Nature Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo (double KO), ChIP-seq, pharmacological validation, replicated with SETD8 re-expression\",\n      \"pmids\": [\"26437366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BAP1's C-terminal extension auto-recruits BAP1 to nucleosomes independently of the acidic patch; the DEUBAD domains of ASXL1, ASXL2, or ASXL3 then activate BAP1 by increasing its affinity for ubiquitin on H2A to drive deubiquitination specifically of H2AK119Ub (Polycomb modification) but not H2AK13/15Ub (DNA damage modification).\",\n      \"method\": \"In vitro reconstituted deubiquitination assay with purified proteins, nucleosome-binding assays, domain deletion/mutation analysis\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with purified components, mechanistic dissection of substrate specificity and activation mechanism\",\n      \"pmids\": [\"26739236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BAP1 localizes to the endoplasmic reticulum (ER), where it binds, deubiquitylates, and stabilizes the type 3 inositol-1,4,5-trisphosphate receptor (IP3R3), thereby modulating Ca2+ release from the ER into the cytosol and mitochondria and promoting apoptosis; reduced BAP1 in BAP1+/- carriers decreases IP3R3 levels and Ca2+ flux, preventing apoptosis after genotoxic stress.\",\n      \"method\": \"Subcellular fractionation, ER localization imaging, Co-IP, in vitro deubiquitination assay, Ca2+ flux measurements, BAP1+/- patient cell lines, cellular transformation assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (localization, DUB assay, Ca2+ flux, functional transformation), validated in patient-derived cells\",\n      \"pmids\": [\"28614305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BAP1 decreases H2Aub occupancy at the SLC7A11 (cystine transporter) promoter and represses SLC7A11 expression in a deubiquitinating-dependent manner, inhibiting cystine uptake and leading to elevated lipid peroxidation and ferroptosis; cancer-associated BAP1 mutants lose ability to repress SLC7A11 and promote ferroptosis.\",\n      \"method\": \"ChIP-seq (H2Aub), RNA-seq, CRISPR/siRNA knockdown, ferroptosis assays, lipid peroxidation measurement, xenograft tumor models\",\n      \"journal\": \"Nature Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — integrated epigenomic + transcriptomic + functional data, catalytic mutant validation, in vivo tumor models\",\n      \"pmids\": [\"30202049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BAP1 inhibits glucose deprivation-induced cell death by repressing the metabolic stress UPR transcriptional network through binding to and inhibiting transcription of ATF3 and CHOP promoters, dependent on its deubiquitinating activity; Bap1 KO mice show enhanced sensitivity to tunicamycin-induced renal damage.\",\n      \"method\": \"ChIP, reporter assays, RNAi, Bap1 KO mice, metabolic stress assays (ROS, ATP measurements)\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct ChIP at ATF3/CHOP promoters, catalytic activity requirement shown, in vivo mouse validation\",\n      \"pmids\": [\"28275095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BAP1 is a component of the DRED γ-globin gene repressor complex and maintains NCoR1 at sites in the β-globin locus through deubiquitinase activity; BAP1 inhibition in erythroid cells massively induces γ-globin synthesis.\",\n      \"method\": \"Co-IP, ChIP, BAP1 inhibition in erythroid cells, γ-globin expression assays\",\n      \"journal\": \"Genes & Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct Co-IP demonstrating complex membership, ChIP at globin locus, functional BAP1 inhibition phenotype\",\n      \"pmids\": [\"30463901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Truncated ASXL1 (gain-of-function frameshift mutant) increases BAP1 protein stability and enhances BAP1 recruitment to chromatin, promoting pro-leukemic transcriptional signatures; BAP1 catalytic inhibitors suppress truncated-ASXL1-driven leukemic gene expression and impair tumor progression in vivo.\",\n      \"method\": \"Biochemical screen for BAP1 inhibitors, western blot, ChIP-seq, in vivo leukemia models\",\n      \"journal\": \"Nature Cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical screen with functional validation, ChIP-seq, in vivo tumor model with catalytic inhibitor\",\n      \"pmids\": [\"35122023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Mutant ASXL1 (C-terminal truncation) increases BAP1's catalytic function via monoubiquitination of ASXL1-MT; the hyperactive ASXL1-MT/BAP1 complex drives myeloid leukaemogenesis by removing H2AK119 ubiquitination at posterior HOXA genes and IRF8, upregulating their expression.\",\n      \"method\": \"Co-IP, in vitro ubiquitination/deubiquitination assays, ChIP-seq (H2AK119ub), gene expression analysis, mouse leukemia models\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical reconstitution of ASXL1-MT/BAP1 activity, ChIP-seq, in vivo mouse model\",\n      \"pmids\": [\"30013160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BAP1 promotes restart of hydroxyurea-induced stalled replication forks by recruiting INO80 to stalled forks; BAP1 depletion abrogates INO80 binding at stalled forks, increases RAD51 foci, reduces S-phase progression under replication stress, and causes hypersensitivity to HU, all rescued by INO80 re-expression.\",\n      \"method\": \"DNA fiber assay, iPOND/ChIP at stalled forks, immunofluorescence, INO80 rescue expression, HU sensitivity assays\",\n      \"journal\": \"The Biochemical Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic rescue with INO80, direct ChIP at stressed forks, multiple orthogonal readouts\",\n      \"pmids\": [\"31657441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BAP1 deubiquitinates and stabilizes PTEN protein; BAP1 physically binds PTEN, removes ubiquitin from PTEN to prevent proteasomal degradation, increases PTEN protein levels, and thereby inhibits AKT signaling and prostate cancer progression.\",\n      \"method\": \"Co-IP, in vitro deubiquitination assay, BAP1 knockdown/overexpression, AKT pathway readouts, xenograft rescue with PTEN re-expression\",\n      \"journal\": \"Molecular Oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical DUB assay with PTEN substrate, reciprocal Co-IP, functional rescue in vivo\",\n      \"pmids\": [\"33155366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BAP1 depletion causes proteasome-mediated degradation of BRCA1 in mesothelioma cells; BAP1 loss leads to spindle assembly checkpoint failure, centrosome amplification, and chromosome segregation errors (BRCA1-dependent), plus increased spindle length and astral microtubule growth due to loss of KIF18A and KIF18B kinesins (BRCA1-independent).\",\n      \"method\": \"BAP1 siRNA depletion, BRCA1 immunoblot with proteasome inhibitor rescue, immunofluorescence mitotic phenotypes, KIF18A/B re-expression rescue\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic separation of BRCA1-dependent and independent pathways, direct rescue by KIF18A/B re-expression\",\n      \"pmids\": [\"36550359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BAP1 depletion in pancreatic cancer leads to enhanced ubiquitin-dependent proteasomal degradation of the Hippo pathway tumor suppressor LATS, deregulating the Hippo pathway and promoting tumor progression.\",\n      \"method\": \"Conditional Bap1 knockout in KrasG12D pancreatic cancer mouse model, LATS ubiquitination/stability assays, Hippo pathway readouts\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic in vivo model, pathway deregulation shown, but LATS as direct BAP1 substrate needs full biochemical confirmation\",\n      \"pmids\": [\"31988076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BAP1 is glutamylated at Glu651 by TTLL5 and TTLL7, and this glutamylation accelerates BAP1 ubiquitination and proteasomal degradation; the carboxypeptidase CCP3 removes glutamylation from BAP1 to stabilize it, enhancing Hoxa1 expression and promoting HSC self-renewal.\",\n      \"method\": \"In vitro glutamylation/deglutamylation assays, ubiquitination assays, CCP3 KO mice, BAP1-E651A knock-in mice, gene expression analysis\",\n      \"journal\": \"The Journal of Experimental Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — novel PTM characterized biochemically, specific residue mutant knock-in mouse, CCP3 KO phenotype validation\",\n      \"pmids\": [\"31699823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BAP1 forms a trimeric protein complex with HMGB1 and HDAC1; reduced BAP1 levels cause increased ubiquitylation and degradation of HDAC1, leading to increased HMGB1 acetylation and its active secretion, which promotes mesothelial cell transformation.\",\n      \"method\": \"Co-IP (trimeric complex identification), ubiquitination assay for HDAC1, HMGB1 acetylation measurement, secretion assay, BAP1+/- patient serum analysis\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — trimeric complex characterized by Co-IP, mechanistic link between BAP1 levels, HDAC1 stability, HMGB1 acetylation demonstrated with patient validation\",\n      \"pmids\": [\"34815344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BAP1 downregulation is required to trigger epithelial-mesenchymal transition (EMT) during trophoblast differentiation; this function depends on BAP1 binding to ASXL1/2 proteins to form the PR-DUB complex, as demonstrated by CRISPR knockout and overexpression in mouse and human trophoblast stem cells.\",\n      \"method\": \"CRISPR/Cas9 KO, BAP1 overexpression, EMT marker analysis, BAP1-ASXL1/2 interaction studies in trophoblast stem cells\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean CRISPR KO and OE in relevant cell type, ASXL binding requirement demonstrated, conserved in human cells\",\n      \"pmids\": [\"34170818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BAP1 cell-intrinsically regulates B lymphocyte development by deubiquitinating histone H2AK119ub; Bap1 conditional deletion in B cells depletes large pre-B cells, transitional, and mature B cells, with broad transcriptional changes mapped by BAP1 ChIP-seq and H2AK119ub profiling.\",\n      \"method\": \"Bap1fl/fl mb1-Cre conditional KO mice, flow cytometry, RNA-seq, ChIP-seq (BAP1 binding, H2AK119ub)\",\n      \"journal\": \"Frontiers in Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO, ChIP-seq demonstrating direct BAP1 occupancy and H2AK119ub changes genome-wide\",\n      \"pmids\": [\"33912157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BAP1 negatively regulates expression of TRAIL receptors DR4 and DR5 through direct interaction with the transcription factor YY1; BAP1 and YY1 are co-enriched at DR4/DR5 promoters by ChIP, and catalytic BAP1 mutant cannot repress DR4/DR5 promoter activity.\",\n      \"method\": \"Co-IP (BAP1-YY1), ChIP at DR4/DR5 promoters, reporter assays with WT and catalytic BAP1 mutant, YY1 siRNA knockdown, tissue microarrays\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, direct ChIP, catalytic mutant functional test, clinical tissue validation\",\n      \"pmids\": [\"34597666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Transportin-1 (TNPO1/Karyopherin β2) targets an atypical C-terminal proline-tyrosine nuclear localization signal (PY-NLS) on BAP1 and serves as its primary nuclear transporter; TNPO1 binding dissociates dimeric BAP1 and sequesters monoubiquitination sites flanking the PY-NLS to counteract UBE2O-mediated cytoplasmic retention of BAP1.\",\n      \"method\": \"Biochemical binding assays, nuclear import assays, domain mutagenesis (PY-NLS), BAP1 dimerization analysis, UBE2O competition assay\",\n      \"journal\": \"The Journal of Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding mapped to specific NLS motif, mechanistic competition between TNPO1 and UBE2O demonstrated, nuclear import assay\",\n      \"pmids\": [\"35446349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structure of human BAP1 with the ASXL1 DEUBAD domain bound to a H2AK119Ub nucleosome reveals molecular interactions of BAP1 and ASXL1 with histones and DNA that restructure the nucleosome and establish specificity for H2AK119Ub; >50 cancer-associated mutations in BAP1 and ASXL1 are mapped to mechanistically explain dysregulation of H2AK119Ub deubiquitination.\",\n      \"method\": \"Cryo-EM structure determination, biochemical reconstitution, cancer mutation structure-function analysis, cellular deubiquitination assays\",\n      \"journal\": \"Science Advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with biochemical and cellular validation, mechanistic explanation of cancer mutations\",\n      \"pmids\": [\"37556531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In osteoclasts, BAP1 deubiquitinase activity regulates osteoclast function through metabolic reprogramming: BAP1 deficiency elevates H2Aub at the SLC7A11 promoter and upregulates SLC7A11 expression, redirecting mitochondrial metabolites from the TCA cycle and altering ROS levels, thereby arresting osteoclast cytoskeletal organization and bone resorption.\",\n      \"method\": \"Bap1 conditional KO in myeloid cells (LysM-Cre), cytoskeletal organization assays, H2Aub ChIP at SLC7A11 promoter, metabolic profiling\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined phenotype, direct ChIP demonstrating epigenetic mechanism, metabolic profiling\",\n      \"pmids\": [\"37740028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BAP1 deubiquitinates and stabilizes MCRS1 (a centrosome component involved in spindle assembly), contributing to chromosome stability in renal cell carcinoma; BAP1 loss reduces MCRS1 levels and induces chromosomal instability.\",\n      \"method\": \"Co-IP, in vitro deubiquitination assay, chromosome stability assays, correlation in ccRCC tissue samples\",\n      \"journal\": \"Cancer Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — DUB assay and Co-IP, but single lab study\",\n      \"pmids\": [\"26300492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BAP1 deubiquitinates and stabilizes DIDO1 (a centrosome component required for spindle assembly) through deubiquitination, thereby maintaining chromosome stability in renal cell carcinoma.\",\n      \"method\": \"Co-IP, in vitro deubiquitination assay, chromosome stability assays, correlation in ccRCC tissues\",\n      \"journal\": \"American Journal of Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — DUB assay, Co-IP, functional chromosome stability readout, single lab\",\n      \"pmids\": [\"32509391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ASXL3 physically interacts with BRD4's extra-terminal (ET) domain via a novel BRD4-binding motif (BBM) and bridges BRD4 to the BAP1 complex; ASXL3 maintains chromatin occupancy of BRD4 at active enhancers in SCLC, and ASXL3 depletion causes genome-wide reduction of H3K27Ac and BRD4-dependent gene expression.\",\n      \"method\": \"Size exclusion chromatography, mass spectrometry, Co-IP, ChIP-seq (BRD4, H3K27Ac), RNA-seq, ASXL3 KO in SCLC cells\",\n      \"journal\": \"Genome Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct interaction mapped biochemically, ChIP-seq, functional gene expression changes with KO\",\n      \"pmids\": [\"32669118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"C-terminally truncated ASXL1 loss of FOXK1/K2 interaction impairs the BAP1-ASXL1-FOXK1/K2 transcriptional network; wild-type ASXL1 interacts with FOXK1/K2 to regulate glucose metabolism, oxygen sensing, and JAK-STAT3 signaling pathway target genes via BAP1, and mutant ASXL1 dominantly inhibits this network.\",\n      \"method\": \"Co-IP (ASXL1-FOXK1/K2-BAP1), selective deletion of mutant allele, RNA-seq, gene expression rescue\",\n      \"journal\": \"Protein & Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP of complex, allele-specific deletion, functional gene expression rescue; single lab\",\n      \"pmids\": [\"32683582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BAP1 deubiquitinates MAFF transcription factor (removing K48-linked ubiquitin) and stabilizes it; stabilized MAFF upregulates DUSP5 expression, which inhibits ERK phosphorylation and suppresses colorectal cancer growth.\",\n      \"method\": \"DUB screening library, Co-IP, in vitro deubiquitination assay, MAFF knockdown/overexpression, ERK pathway readouts, xenograft models\",\n      \"journal\": \"European Journal of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — DUB assay, Co-IP, functional downstream pathway validation, in vivo model; single lab\",\n      \"pmids\": [\"39151323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BAP1 protects against disulfidptosis by suppressing SLC7A11-mediated cystine uptake (via H2Aub deubiquitination at SLC7A11 promoter) and by maintaining NADPH levels; loss of BAP1 or overexpression of SLC7A11 promotes disulfidptosis under glucose starvation.\",\n      \"method\": \"Cell death inhibitor profiling, disulfide bond accumulation assays, SLC7A11 KO/overexpression, erastin treatment, NADP+/NADPH measurement\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell death inhibitors and genetic manipulations, mechanistic link through SLC7A11; single lab\",\n      \"pmids\": [\"39266549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BAP1 overexpression enhances P53 activity and stability by reducing proteasome-mediated P53 degradation; the transcription factor ATF2 regulates BAP1 expression by binding the BAP1 promoter, placing BAP1 in an ATF2-BAP1-P53 axis mediating neuronal apoptosis.\",\n      \"method\": \"Luciferase assay (ATF2 binding to BAP1 promoter), Co-IP, P53 ubiquitination/stability assays, BAP1 shRNA knockdown in mouse SAH model\",\n      \"journal\": \"Stroke\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase and Co-IP for upstream regulation, P53 stability mechanistic link, in vivo mouse model; single lab\",\n      \"pmids\": [\"38965653\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BAP1 is a nuclear (and ER-localized) deubiquitinase whose primary chromatin substrate is H2AK119Ub; it is activated by ASXL1/2/3 DEUBAD domains and operates as the catalytic subunit of the Polycomb repressive deubiquitinase (PR-DUB) complex, where its specificity for H2AK119Ub over other nucleosomal ubiquitin sites is established by restructuring the nucleosome (as revealed by cryo-EM); beyond histones, BAP1 deubiquitinates and stabilizes multiple protein substrates including HCF-1, IP3R3 (at the ER to regulate Ca2+ flux and apoptosis), INO80 (to promote DNA replication fork progression), PTEN, KLF5, MCRS1, DIDO1, and MAFF; it represses SLC7A11 transcription via H2Aub removal to suppress cystine uptake and promote ferroptosis; its nuclear import is governed by transportin-1 targeting a PY-NLS, competing with UBE2O-mediated monoubiquitination; and it is regulated post-translationally by phosphorylation (required for DSB repair) and glutamylation at Glu651 (controlling its own stability in HSCs).\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BAP1 is a nuclear deubiquitinase that serves as the catalytic subunit of the Polycomb repressive deubiquitinase (PR-DUB) complex, coupling histone H2AK119Ub removal with transcriptional regulation, DNA repair, replication fork progression, calcium-mediated apoptosis, and ferroptosis. Activated by ASXL1/2/3 DEUBAD domains that generate a composite ubiquitin-binding interface conferring specificity for H2AK119Ub over DNA-damage-associated H2AK13/15Ub, BAP1 restructures the nucleosome to access its substrate, as revealed by cryo-EM [PMID:37556531, PMID:26739236]. Beyond histones, BAP1 deubiquitinates and stabilizes diverse protein substrates—including HCF-1, IP3R3 at the ER (promoting Ca²⁺ flux and apoptosis), INO80 (enabling replication fork restart), PTEN, KLF5, and HDAC1—thereby integrating chromatin remodeling with cell proliferation, genomic stability, and metabolic control [PMID:19815555, PMID:28614305, PMID:25283999, PMID:33155366, PMID:26419610, PMID:34815344]. BAP1 represses SLC7A11 transcription through H2Aub removal to restrict cystine uptake and sensitize cells to ferroptosis, and its nuclear import is governed by transportin-1 recognition of a C-terminal PY-NLS that competes with UBE2O-mediated cytoplasmic retention, while its stability is modulated by glutamylation at Glu651 [PMID:30202049, PMID:35446349, PMID:31699823].\",\n  \"teleology\": [\n    {\n      \"year\": 2009,\n      \"claim\": \"Identifying HCF-1 as a direct BAP1 substrate established that BAP1 functions as a deubiquitinase for non-histone proteins with roles in cell proliferation, not solely as a chromatin modifier.\",\n      \"evidence\": \"Mass spectrometry, reciprocal Co-IP, in vitro DUB assay, and HBM-mutant functional analysis in human cells\",\n      \"pmids\": [\"19815555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HCF-1 deubiquitination is the primary mechanism of BAP1 tumor suppression was unresolved\", \"Full repertoire of BAP1 substrates unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapping BAP1 inactivating mutations to the UCH catalytic domain in metastasizing uveal melanomas established that deubiquitinase activity is essential for BAP1's tumor-suppressive function.\",\n      \"evidence\": \"Exome sequencing of uveal melanomas with mutation mapping to the UCH domain\",\n      \"pmids\": [\"21051595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The critical substrate(s) mediating tumor suppression were not identified\", \"Whether catalytic activity is the sole tumor-suppressive mechanism was unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating that HCF-1 binding and H2AK119Ub deubiquitination are separable BAP1 functions revealed that BAP1 tumor suppression involves multiple independent downstream pathways.\",\n      \"evidence\": \"Tumorgraft fractionation, HBM-mutant analysis distinguishing proliferation control from H2A DUB activity in renal cell carcinoma\",\n      \"pmids\": [\"22683710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of H2A DUB versus HCF-1 DUB to tumor suppression in different cancer types unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showing that BAP1 is recruited to DSB sites and that both catalytic activity and IR-induced phosphorylation are required for HR-mediated repair placed BAP1 in the DNA damage response and revealed phosphorylation as a regulatory input.\",\n      \"evidence\": \"DT40 knockout, immunofluorescence foci, ChIP at I-SceI sites, phospho-site mutagenesis\",\n      \"pmids\": [\"24347639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the kinase(s) phosphorylating BAP1 after IR not determined\", \"Precise DUB substrate at DSBs not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of INO80 as a BAP1 substrate that is stabilized by deubiquitination and recruited to replication forks extended BAP1 function from transcription and repair to DNA replication fork progression.\",\n      \"evidence\": \"Co-IP, in vitro DUB assay, ChIP at replication forks in BAP1-defective cancer cells\",\n      \"pmids\": [\"25283999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BAP1 senses replication stress to recruit INO80 was not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Biochemical reconstitution showing that ASXL1/2 DEUBAD domains form a composite ubiquitin-binding interface with BAP1 and activate H2AK119Ub-specific (but not H2AK13/15Ub) deubiquitination defined the PR-DUB activation mechanism and its substrate selectivity.\",\n      \"evidence\": \"In vitro reconstitution with purified proteins, nucleosome-binding assays, domain deletion/mutation analysis\",\n      \"pmids\": [\"26739236\", \"26416890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for selectivity between H2AK119Ub and H2AK13/15Ub not resolved at atomic level\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Genetic epistasis between Bap1 loss and Ezh2 deletion in mice revealed that BAP1 indirectly opposes PRC2-mediated H3K27me3 through effects on H4K20me1 and EZH2 levels, placing BAP1 in a Polycomb regulatory circuit.\",\n      \"evidence\": \"Bap1/Ezh2 double conditional KO mice, ChIP-seq for H3K27me3 and H4K20me1, pharmacological EZH2 inhibition\",\n      \"pmids\": [\"26437366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BAP1 directly or indirectly controls EZH2 expression levels was not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Discovery that BAP1 localizes to the ER where it deubiquitinates and stabilizes IP3R3 to promote Ca²⁺-mediated apoptosis established a non-chromatin tumor-suppressive mechanism operating through calcium signaling.\",\n      \"evidence\": \"Subcellular fractionation, ER imaging, DUB assay, Ca²⁺ flux measurement, BAP1+/− patient-derived cells\",\n      \"pmids\": [\"28614305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BAP1 partitions between nucleus and ER was not mechanistically explained\", \"ER-specific interactors beyond IP3R3 not catalogued\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstration that BAP1 represses SLC7A11 by removing H2Aub at its promoter, thereby restricting cystine uptake and sensitizing cells to ferroptosis, linked BAP1's epigenetic activity to a specific regulated cell death pathway.\",\n      \"evidence\": \"ChIP-seq for H2Aub, RNA-seq, ferroptosis and lipid peroxidation assays, catalytic mutant analysis, xenograft models\",\n      \"pmids\": [\"30202049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ferroptosis contributes to BAP1's tumor-suppressive activity in patients was not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Finding that truncated ASXL1 gain-of-function mutants increase BAP1 stability, chromatin recruitment, and H2AK119Ub removal at HOXA loci to drive myeloid leukemogenesis revealed how oncogenic ASXL1 mutations hijack normal PR-DUB activity.\",\n      \"evidence\": \"Co-IP, ChIP-seq for H2AK119ub, in vivo leukemia models, BAP1 catalytic inhibitor validation\",\n      \"pmids\": [\"30013160\", \"35122023\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BAP1 catalytic inhibitors are therapeutically viable in ASXL1-mutant leukemia patients not tested clinically\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of glutamylation at Glu651 as a degradation signal for BAP1—installed by TTLL5/7 and removed by CCP3—revealed a novel post-translational regulatory layer controlling BAP1 stability in hematopoietic stem cells.\",\n      \"evidence\": \"In vitro glutamylation/deglutamylation assays, BAP1-E651A knock-in mice, CCP3 KO mice\",\n      \"pmids\": [\"31699823\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether glutamylation regulates BAP1 in non-hematopoietic tissues is unknown\", \"Identity of the E3 ligase triggered by glutamylation not determined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Expanding BAP1's substrate repertoire to include PTEN established a direct link between BAP1 deubiquitinase activity and suppression of PI3K-AKT signaling in cancer.\",\n      \"evidence\": \"Reciprocal Co-IP, in vitro DUB assay on PTEN, AKT pathway readouts, xenograft rescue with PTEN re-expression\",\n      \"pmids\": [\"33155366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PTEN stabilization is relevant across all BAP1-mutant cancer types or tissue-specific\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mapping transportin-1 recognition of BAP1's PY-NLS and its competition with UBE2O-mediated monoubiquitination explained how BAP1 nuclear-cytoplasmic distribution is actively regulated, resolving the question of how BAP1 partitions between nuclear and ER functions.\",\n      \"evidence\": \"Biochemical binding assays, nuclear import assays, PY-NLS mutagenesis, UBE2O competition assay\",\n      \"pmids\": [\"35446349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal(s) that shift the TNPO1–UBE2O balance in physiological or stress contexts not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The cryo-EM structure of BAP1–ASXL1 DEUBAD bound to H2AK119Ub nucleosome resolved at atomic detail how PR-DUB achieves substrate specificity by restructuring the nucleosome, and structurally rationalized >50 cancer mutations.\",\n      \"evidence\": \"Cryo-EM structure determination, biochemical reconstitution, cellular DUB assays, cancer mutation mapping\",\n      \"pmids\": [\"37556531\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structures with ASXL2 or ASXL3 not determined\", \"How the PR-DUB complex is recruited to specific genomic loci rather than acting genome-wide remains unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BAP1 is targeted to specific genomic loci (beyond FoxK2- and YY1-mediated recruitment) to achieve gene-selective H2AK119Ub removal, and how its nuclear versus ER functions are coordinately regulated under physiological conditions, remain major open questions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide determinants of BAP1 locus specificity not systematically defined\", \"Relative contributions of chromatin vs. ER-based tumor suppression not quantified in vivo\", \"Whether BAP1 catalytic inhibitors represent viable cancer therapeutics is untested clinically\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 6, 7, 9, 10, 11, 17, 26, 28, 29, 32]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 7, 9, 10, 17, 28, 29, 32]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [9, 11, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 3, 5, 9, 11, 23, 25, 26]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [3, 9, 26]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [2, 5, 8, 9, 11, 15, 23, 26, 27]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [3, 16]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [4, 16]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 11, 13, 24]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 11, 33]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [7, 18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 14, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [17, 19]}\n    ],\n    \"complexes\": [\n      \"PR-DUB (Polycomb repressive deubiquitinase)\",\n      \"DRED γ-globin repressor complex\",\n      \"BAP1-HMGB1-HDAC1 complex\"\n    ],\n    \"partners\": [\n      \"ASXL1\",\n      \"ASXL2\",\n      \"ASXL3\",\n      \"HCF1\",\n      \"FOXK2\",\n      \"INO80\",\n      \"TNPO1\",\n      \"YY1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}